33.33
0.16 (0.48%)
| Previous Close | 33.17 |
| Open | 33.48 |
| Volume | 768,759 |
| Avg. Volume (3M) | 1,275,301 |
| Market Cap | 6,121,021,440 |
| Price / Earnings (Forward) | 1.00 |
| Price / Sales | 9.67 |
| Price / Book | 5.85 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 |
| Profit Margin | -28.22% |
| Operating Margin (TTM) | -40.19% |
| Diluted EPS (TTM) | -0.960 |
| Quarterly Revenue Growth (YOY) | 134.70% |
| Total Debt/Equity (MRQ) | 33.69% |
| Current Ratio (MRQ) | 4.62 |
| Operating Cash Flow (TTM) | -144.03 M |
| Levered Free Cash Flow (TTM) | -38.58 M |
| Return on Assets (TTM) | -10.84% |
| Return on Equity (TTM) | -15.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Legend Biotech Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.33% |
| % Held by Institutions | 55.58% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 84.00 (RBC Capital, 152.03%) | Buy |
| Median | 80.00 (140.02%) | |
| Low | 75.00 (HC Wainwright & Co., 125.02%) | Buy |
| Average | 79.67 (139.03%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 35.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 22 Apr 2025 | 84.00 (152.03%) | Buy | 34.48 |
| HC Wainwright & Co. | 16 Apr 2025 | 75.00 (125.02%) | Buy | 33.46 |
| 08 Apr 2025 | 75.00 (125.02%) | Buy | 30.77 | |
| Morgan Stanley | 17 Mar 2025 | 80.00 (140.02%) | Buy | 37.94 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Apr 2025 | Announcement | Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results |
| 11 Mar 2025 | Announcement | Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights |
| 25 Feb 2025 | Announcement | Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |